{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000442","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.925932+00:00","generated_at":"2026-06-20T17:53:21.378449+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Treace Medical beats FY22 revenue guidance; Q4 revenue up ~47-48% YoY","bullets":["Preliminary Q4 2022 revenue $49.1M-$49.6M, up 47-48% YoY.","Preliminary FY22 revenue $141.2M-$141.7M, up ~50% YoY, above prior guidance of $135M-$138M.","CEO cites strength of direct sales channel, DTC programs, and R&D investments.","Company plans to provide 2023 guidance on Q4 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000442","json":"https://secwatch.observer/filing/0000950170-23-000442.json","markdown":"https://secwatch.observer/filing/0000950170-23-000442.md","text":"https://secwatch.observer/filing/0000950170-23-000442.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023000442/0000950170-23-000442-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023000442/tmci-20230109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:53:21.378449+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d4d8372a0e40914a41adb2d62d9a72049f593608","claim":"TREACE MEDICAL CONCEPTS, INC. reported fourth quarter and full year 2022 results: revenue $49.1 to $49.6 million and $141.2 to $141.7 million, respectively.","evidence_excerpt":"preliminary unaudited results for fourth quarter and full year 2022. Preliminary unaudited revenue for the fourth quarter and full year 2022 is anticipated to be in the range of $49.1 to $49.6 million and $141.2 to $141.7 million, respectively, representing an increase in the range of 47% to 48% and 50% over the same periods last year, respectively. The full","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1630627/000095017023000442/0000950170-23-000442-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2022"},{"label":"Revenue","value":"$49.1 to $49.6 million and $141.2 to $141.7 million, respectively"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}